Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Radiology

Confirming the Diagnosis: Imaging and Testing

At a Glance

A chest wall lipoma is usually benign and can be assessed with ultrasound, MRI, or CT based on its size and location. If imaging raises concern for an atypical lipomatous tumor, a specialist-planned core biopsy and sometimes MDM2 testing can help clarify the diagnosis.

Confirming that a chest wall mass is a simple lipoma requires a systematic diagnostic approach. Because lipomas can look very similar to more complex tumors, your medical team uses a combination of advanced imaging and detailed tissue testing to provide a definitive answer [1][2]. This process ensures that you receive the correct treatment while avoiding unnecessary or poorly planned procedures.

The First Look: Imaging

The diagnostic journey usually begins with imaging. Your doctor will choose a tool based on the location and size of the lump.

  • Ultrasound: This is often the first test for a lump you can feel just under the skin. It is excellent at distinguishing between a solid mass (like a lipoma) and a fluid-filled sac (like a cyst) [1][3].
  • MRI (Magnetic Resonance Imaging): This is the preferred imaging method for many deep soft-tissue masses [3]. An MRI provides a detailed map of the mass and its relationship to the surrounding muscles and nerves. It is particularly important for any lump larger than 5 centimeters or any mass located deep beneath the muscle layer (subfascial) [4][5].
  • CT Scan: While MRI is better for looking at soft tissue, a CT scan is often more appropriate for assessing intrathoracic lipomas (inside the chest) and evaluating if the tumor is involving the ribs, lungs, or major blood vessels [6][7].

Distinguishing Lipomas from Liposarcoma

The most critical part of the diagnosis is distinguishing a benign lipoma from an Atypical Lipomatous Tumor (ALT), also known as Well-Differentiated Liposarcoma (the terms used depend on the tumor’s exact location). While an ALT rarely spreads to other parts of the body, it requires a more extensive surgical approach than a simple lipoma because it has a higher risk of growing back if any part is left behind [4][8].

On an MRI, radiologists look for specific “markers” that suggest a tumor might be an ALT rather than a simple lipoma:

  • Thick Septa: Benign lipomas have very thin internal lines (septa). If these lines are thicker than 2 millimeters or look irregular, it increases the suspicion of ALT [9][10].
  • Nodules: The presence of small, solid lumps or non-fatty “nodules” within the mass is a warning sign [10][11].
  • Size and Depth: Tumors that are very large (often over 10 centimeters) or located deep in the muscle are statistically more likely to require a closer look [4][12].

The Critical Biopsy Checklist

If imaging cannot rule out a more serious tumor, a biopsy may be necessary. Where and how this biopsy is performed is the most important decision in your care.

1. The Sarcoma Center Rule

If there is even a small suspicion that your lump could be a sarcoma (a soft-tissue cancer), your biopsy should be planned in consultation with a specialized sarcoma center or experienced multidisciplinary team [4][13]. These centers use a multidisciplinary team (MDT) of surgeons, radiologists, and pathologists who specialize only in these rare tumors [2][14].

2. Protecting the “Biopsy Tract”

When a needle enters a tumor, there is a tiny risk that it could pull tumor cells back through the path it took. This path is called the biopsy tract. In a specialized center, the surgeon and radiologist plan the needle’s path together so that the entire tract can be removed during the final surgery [13][15]. If a biopsy tract is poorly planned at a local clinic, the tract might cross through healthy tissues, potentially making the eventual surgery much more difficult and increasing the risk of the tumor returning [16][17].

3. Core Needle Biopsy

The standard technique is a core needle biopsy (CNB). Unlike a simple needle aspiration that only pulls out a few cells, a CNB takes a small “core” of tissue, allowing the pathologist to see the actual architecture of the cells [18][19].

Pathology and the MDM2 Test

Once a tissue sample is taken, it is sent to a pathologist. To distinguish a benign lipoma from an ALT in diagnostically difficult cases, pathologists may use an adjunct molecular test called MDM2 amplification [20][21].

  • How it works: Most ALTs have extra copies of a gene called MDM2. Pathologists use a technique called FISH (Fluorescence In Situ Hybridization), where they use glowing probes to literally count the number of MDM2 genes inside the cells [22][23].
  • The Result: If the test shows “amplification” (too many copies) of the MDM2 gene, it supports a diagnosis of ALT. If the gene count is normal, this does not independently prove it is benign; the result must be integrated with imaging and pathology by an expert, as sampling or technical limitations can occur [20][24].

Because biopsies only take a small sample of a potentially large tumor, there is a risk of “sampling error” where the needle misses the most active part of the growth [25][26]. This is why your medical team will always look at your MRI results, your physical symptoms, and your pathology report together rather than relying on any single test in isolation [27][28]. Note that classic, conventional lipomas usually do not require molecular testing at all.

Common questions in this guide

What imaging test is used to diagnose a chest wall lipoma?
Ultrasound is often the first test for a lump just under the skin. MRI is preferred for many deep soft-tissue masses and for lumps larger than 5 centimeters, while CT may be more useful for a mass inside the chest or near the ribs, lungs, or major blood vessels.
What MRI findings could mean that a chest wall lump is not a simple lipoma?
Thick or irregular internal bands, called septa, and solid areas or non-fatty nodules can raise concern for an atypical lipomatous tumor. Very large or deep masses may also need closer evaluation. Imaging findings are interpreted together rather than used alone to make the diagnosis.
Does every chest wall lipoma need a biopsy?
No. A biopsy may be recommended when imaging cannot confidently rule out an atypical lipomatous tumor or another soft-tissue tumor. When a biopsy is needed, a core needle biopsy provides a tissue sample that lets the pathologist examine the structure of the cells.
Why should a suspected chest wall sarcoma biopsy be planned by specialists?
If a soft-tissue cancer is possible, a sarcoma team should help plan the biopsy route. The needle path, also called the biopsy tract, can then be removed during later surgery if necessary. A poorly placed tract may pass through healthy tissue and make future surgery more difficult.
What does an MDM2 FISH test show?
MDM2 FISH is a laboratory test that counts copies of the MDM2 gene in tumor cells. Extra copies support a diagnosis of an atypical lipomatous tumor, but a normal result does not by itself prove that a mass is benign. The result must be interpreted with the imaging and the rest of the pathology.
Can a biopsy miss the concerning part of a chest wall tumor?
Yes. Because a biopsy samples only a small part of a larger mass, it can miss the most active or unusual area; this is called sampling error. Doctors reduce this risk by considering the imaging, physical findings, and pathology together instead of relying on one test alone.

Get notified when new evidence is published on chest wall lipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (28)
  1. 1

    Management of adipose tumors in the limbs.

    Le Nail LR, Crenn V, Rosset P, Ropars M

    Orthopaedics & traumatology, surgery & research : OTSR 2022; (108(1S)):103162 doi:10.1016/j.otsr.2021.103162.

    PMID: 34863958
  2. 2

    Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors.

    Shu C, Lim M, Fang A

    Life (Basel, Switzerland) 2023; (13(7)) doi:10.3390/life13071485.

    PMID: 37511864
  3. 3

    Increasing differential diagnosis between lipoma and liposarcoma through radiomics: a narrative review.

    Natella R, Varriano G, Brunese MC, et al.

    Exploration of targeted anti-tumor therapy 2023; (4(3)):498-510 doi:10.37349/etat.2023.00147.

    PMID: 37455823
  4. 4

    Lipomatous Soft-tissue Tumors.

    Johnson CN, Ha AS, Chen E, Davidson D

    The Journal of the American Academy of Orthopaedic Surgeons 2018; (26(22)):779-788 doi:10.5435/JAAOS-D-17-00045.

    PMID: 30192249
  5. 5

    Qualitative evaluation of MRI features of lipoma and atypical lipomatous tumor: results from a multicenter study.

    Nardo L, Abdelhafez YG, Acquafredda F, et al.

    Skeletal radiology 2020; (49(6)):1005-1014 doi:10.1007/s00256-020-03372-5.

    PMID: 31965239
  6. 6

    Imaging review of lipomatous musculoskeletal lesions.

    Burt AM, Huang BK

    SICOT-J 2017; (3()):34 doi:10.1051/sicotj/2017015.

    PMID: 28474576
  7. 7

    Chest wall lipoma mimicking intrathoracic mass: Imaging with surgical correlation.

    Schicchi N, Tiberi M, Fogante M, et al.

    Radiology case reports 2019; (14(8)):956-961 doi:10.1016/j.radcr.2019.05.020.

    PMID: 31193853
  8. 8

    The recurrence of well-differentiated liposarcoma from benign giant intramuscular lipoma: A case (CARE-compliant) report.

    Lee YJ, Cha WJ, Kim Y, Oh DY

    Medicine 2021; (100(6)):e24711 doi:10.1097/MD.0000000000024711.

    PMID: 33578611
  9. 9

    Spectrum of Fat-containing Soft-Tissue Masses at MR Imaging: The Common, the Uncommon, the Characteristic, and the Sometimes Confusing.

    Gupta P, Potti TA, Wuertzer SD, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2016; (36(3)):753-66 doi:10.1148/rg.2016150133.

    PMID: 27163592
  10. 10

    Differentiating atypical lipomatous tumors from lipomas with magnetic resonance imaging: a comparison with MDM2 gene amplification status.

    Knebel C, Neumann J, Schwaiger BJ, et al.

    BMC cancer 2019; (19(1)):309 doi:10.1186/s12885-019-5524-5.

    PMID: 30943944
  11. 11

    Differentiation of Atypical Lipomatous Tumors from Lipomas: Our Experience with Visual Analysis of Conventional Magnetic Resonance Imaging.

    Moran LM, Li Cai CY, Ramirez A, Royuela A

    Journal of imaging 2025; (11(2)) doi:10.3390/jimaging11020047.

    PMID: 39997549
  12. 12

    Diagnostic accuracy of CT and MR features for detecting atypical lipomatous tumors and malignant liposarcomas: a systematic review and meta-analysis.

    Wilson MP, Haidey J, Murad MH, et al.

    European radiology 2023; (33(12)):8605-8616 doi:10.1007/s00330-023-09916-2.

    PMID: 37439933
  13. 13

    [Management of soft tissue sarcomas : guidelines for the diagnosis and treatment].

    Neuberg M, Decker E, Gennigens C, et al.

    Revue medicale de Liege 2025; (80(5-6)):330-333.

    PMID: 40518886
  14. 14

    Percutaneous Imaging-Guided versus Open Musculoskeletal Biopsy: Concepts and Controversies.

    Vasilevska Nikodinovska V, Ivanoski S, Samardziski M, Janevska V

    Seminars in musculoskeletal radiology 2020; (24(6)):667-675 doi:10.1055/s-0040-1717113.

    PMID: 33307583
  15. 15

    [General principles of biopsy technique and approaches in soft tissue and bone sarcomas].

    Ploeger MM, V Hattem S, Alex D, et al.

    Operative Orthopadie und Traumatologie 2026; (38(1)):3-10 doi:10.1007/s00064-025-00926-5.

    PMID: 41575504
  16. 16

    Are Biopsy Tracts a Concern for Seeding and Local Recurrence in Sarcomas?

    Barrientos-Ruiz I, Ortiz-Cruz EJ, Serrano-Montilla J, et al.

    Clinical orthopaedics and related research 2017; (475(2)):511-518 doi:10.1007/s11999-016-5090-y.

    PMID: 27655183
  17. 17

    Pre-operative evaluation prior to soft tissue sarcoma excision - Why can't we get it right?

    Mesko NW, Wilson RJ, Lawrenz JM, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2018; (44(2)):243-250 doi:10.1016/j.ejso.2017.11.001.

    PMID: 29269109
  18. 18

    Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: A systematic review and meta-analysis.

    Birgin E, Yang C, Hetjens S, et al.

    Cancer 2020; (126(9)):1917-1928 doi:10.1002/cncr.32735.

    PMID: 32022262
  19. 19

    Safety and Accuracy of Core Needle Biopsy for Soft Tissue Masses in an Ambulatory Setting.

    Walker JB, Stockwell E, Worhacz K, et al.

    Sarcoma 2018; (2018()):1657864 doi:10.1155/2018/1657864.

    PMID: 30008580
  20. 20

    MDM2 Amplification in Problematic Lipomatous Tumors: Analysis of FISH Testing Criteria.

    Clay MR, Martinez AP, Weiss SW, Edgar MA

    The American journal of surgical pathology 2015; (39(10)):1433-9 doi:10.1097/PAS.0000000000000468.

    PMID: 26146760
  21. 21

    MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective.

    Clay MR, Martinez AP, Weiss SW, Edgar MA

    The American journal of surgical pathology 2016; (40(12)):1647-1652 doi:10.1097/PAS.0000000000000713.

    PMID: 27508976
  22. 22

    Criteria for MDM2 fluorescence in situ hybridization testing in the diagnosis of well-differentiated adipocytic neoplasms: a retrospective utilization review of 1151 cases.

    Flaman AN, Zhang L, Dickson BC, Demicco EG

    Virchows Archiv : an international journal of pathology 2025; (487(6)):1279-1289 doi:10.1007/s00428-025-04342-9.

    PMID: 41269286
  23. 23

    MDM4 amplification in atypical lipomatous tumors/well-differentiated liposarcoma: Private event or alternative oncogenic mechanism?

    Gruel N, El Zein S, Tzanis D, et al.

    Genes, chromosomes & cancer 2023; (62(6)):367-372 doi:10.1002/gcc.23130.

    PMID: 36744846
  24. 24

    MDM2 RNA In Situ Hybridization for the Diagnosis of Atypical Lipomatous Tumor: A Study Evaluating DNA, RNA, and Protein Expression.

    Kulkarni AS, Wojcik JB, Chougule A, et al.

    The American journal of surgical pathology 2019; (43(4)):446-454 doi:10.1097/PAS.0000000000001199.

    PMID: 30520819
  25. 25

    Lessons learnt from MDM2 fluorescence in-situ hybridisation analysis of 439 mature lipomatous lesions with an emphasis on atypical lipomatous tumour/well-differentiated liposarcoma lacking cytological atypia.

    Vargas AC, Joy C, Cheah AL, et al.

    Histopathology 2022; (80(2)):369-380 doi:10.1111/his.14558.

    PMID: 34523152
  26. 26

    Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center.

    Thway K, Wang J, Swansbury J, et al.

    Sarcoma 2015; (2015()):812089 doi:10.1155/2015/812089.

    PMID: 25810689
  27. 27

    The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing.

    Ryan S, Visgauss J, Kerr D, et al.

    Sarcoma 2018; (2018()):1901896 doi:10.1155/2018/1901896.

    PMID: 29755284
  28. 28

    Atypical lipomatous tumor/well differentiated liposarcoma and related mimics with updates. When is molecular testing most cost-effective, necessary, and indicated?

    Kilpatrick SE

    Human pathology 2024; (147()):82-91 doi:10.1016/j.humpath.2023.12.005.

    PMID: 38135062

This page is for informational purposes only and does not constitute medical advice. Your radiologist, surgeon, and pathologist can explain what your imaging and biopsy results mean for your specific situation.

Guide contents chest wall lipoma
Research & Literature
02 Symptoms and Warning Signs 04 Treatment Strategies